ScholarIQanswers from OpenAlex & ORCID
Saad Z. Usmani
ResearcherPublications, citations & collaboration network
Saad Z. Usmani is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Saad Z. Usmani have?
ScholarIQindexed works
Saad Z. Usmani has 1,048 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Saad Z. Usmani have?
ScholarIQcitation count
Saad Z. Usmani has 40,049 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Saad Z. Usmani?
ScholarIQh-index
Saad Z. Usmani has an h-index of 86 in OpenAlex.
What is the i10-index of Saad Z. Usmani?
ScholarIQi10-index
Saad Z. Usmani has an i10-index of 306 in OpenAlex.
What is the ORCID of Saad Z. Usmani?
ScholarIQorcid
The ORCID for Saad Z. Usmani is on the source record.
What is the OpenAlex record for Saad Z. Usmani?
ScholarIQopenalex
The OpenAlex for Saad Z. Usmani is on the source record.
What are the most-cited papers on Saad Z. Usmani?
ScholarIQmost cited works
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar, Bruno Paiva, Kenneth C. Anderson, Brian G.M. Durie, Ola Landgren, Philippe Moreau, Nikhil C. Munshi, Sagar Lonial, Joan Bladé, María‐Victoria Mateos, Meletios Α. Dimopoulos, Efstathios Kastritis, Mario Boccadoro, Robert Z. Orlowski, Hartmut Goldschmidt, Andrew Spencer, Jian Hou, Wee Joo Chng, Saad Z. Usmani, Elena Zamagni, Kazuyuki Shimizu, Sundar Jagannath, Hans Erik Johnsen, Evangelos Terpos, Tony Reiman, Robert A. Kyle, Pieter Sonneveld, Paul G. Richardson, Philip L. McCarthy, Heinz Ludwig, Wen-Ming Chen, Michèle Cavo, Jean‐Luc Harousseau, Suzanne Lentzsch, Jens Hillengaß, Antonio Palumbo, Alberto Órfão, S. Vincent Rajkumar, Jesús F. San Miguel, Hervé Avet‐Loiseau
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, A. Keith Stewart, Parameswaran Hari, Myo Htut, Alexander M. Lesokhin, Abhinav Deol, Nikhil C. Munshi, Elizabeth O’Donnell, David Avigan, Indrajeet Singh, Enrique Zudaire, Tzu‐Min Yeh, Alicia J. Allred, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Jenna D Goldberg, Jordan M. Schecter, William Deraedt, Sen Hong Zhuang, Jeffrey R. Infante, Dong Geng, Xiaoling Wu, Marlene J. Carrasco-Alfonso, Muhammad Akram, Farah Hossain, Syed Rizvi, Frank Fan, Yi Lin, Thomas G. Martin, Sundar Jagannath
Teclistamab in Relapsed or Refractory Multiple Myeloma
Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel, Albert Oriol, Ajay K. Nooka, Thomas G. Martin, Laura Rosiñol, Ajai Chari, Lionel Karlin, Lotfi Benboubker, María‐Victoria Mateos, Nizar J. Bahlis, Rakesh Popat, Britta Besemer, Joaquín Martínez‐López, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Raluca Verona, Suzette Girgis, Shun Xin Wang Lin, Yunsi Olyslager, Mindy Jaffe, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Jenna D. Goldberg, Rachel Kobos, Amrita Krishnan, Saad Z. Usmani
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al‐Ola Abdallah, Natalie S. Callander, Nikoletta Lendvai, Douglas W. Sborov, Attaya Suvannasankha, Katja Weisel, Lionel Karlin, Edward N. Libby, Bertrand Arnulf, Thierry Façon, Cyrille Hulin, K. Martin Kortüm, Paula Rodríguez‐Otero, Saad Z. Usmani, Parameswaran Hari, Rachid Baz, Hang Quach, Philippe Moreau, Peter M. Voorhees, Ira Gupta, Axel Hoos, Eric Zhi, January Baron, Trisha Piontek, Eric Lewis, Roxanne C. Jewell, Elisha J. Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul G. Richardson, Adam D. Cohen
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah, Ajai Chari, Emma Scott, Khalid Mezzi, Saad Z. Usmani